Lv61
2070 积分 2025-01-07 加入
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
1小时前
已完结
Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
2小时前
已关闭
Society of Family Planning Committee Statement: Contraception and body weight
2小时前
已完结
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes
2小时前
已完结
Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons
2小时前
已完结
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients
3小时前
已完结
基于FAERS数据库联合孟德尔随机化探究奥希替尼ILD易感因素
5天前
已完结
Cardiotoxicity of macrolide antibiotics: a pharmacovigilance study integrating FAERS and JADER databases
12天前
已完结
The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation
15天前
已完结
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon‐Like Peptide‐1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis
16天前
已完结
皖公网安备34019202002308
